Physician profile
Daniel Chakos
NPI 1487034674
$1,467.17
in general payments reported to CMS, 2019-2025
23 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2022: $78.89 · 2023: $585 · 2024: $200 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $215.67 | 2023-2025 | |
| Genentech USA, INC. | $173.08 | 2022-2025 | Kadcyla, Phesgo, Perjeta |
| Janssen Biotech, INC. | $155.98 | 2025 | Rybrevant, Carvykti, Darzalex |
| Astellas Pharma US INC | $145.75 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $106.19 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Pfizer INC. | $103.93 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.03 | 2023 | Fruzaqla, Alunbrig, Ninlaro |
| Merck Sharp & Dohme LLC | $63.22 | 2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $49.34 | 2023 | Myrisk |
| Incyte Corporation | $49.01 | 2023-2025 | Jakafi, Monjuvi |
| Seagen INC. | $45.96 | 2023 | Adcetris, Tukysa |
| Regeneron Healthcare Solutions, INC. | $36.59 | 2024 | Libtayo |
| G1 Therapeutics, INC. | $36.08 | 2022-2023 | Cosela |
| Abbvie INC. | $30.96 | 2024-2025 | |
| Foundation Medicine, INC. | $28.15 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.93 | 2024 | Enhertu |
| Beone Medicines USA, INC. | $24.27 | 2025 | Tevimbra |
| Puma Biotechnology, INC. | $22.94 | 2023 | |
| Gilead Sciences, INC. | $21.54 | 2023 | |
| Celgene Corporation | $19.41 | 2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $14.67 | 2022 | |
| Janssen Scientific Affairs, LLC | $11.97 | 2019 | |
| Amgen INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chakos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.